These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29246642)

  • 1. Reply to Georgios Papadopoulos, Charalampos Fragkoulis, and Konstantinos Ntoumas' Letter to the Editor re: Bimal Bhindi, Igor Frank, Ross J. Mason, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol 2017;72:660-4.
    Bhindi B; Boorjian SA
    Eur Urol; 2018 Mar; 73(3):e53. PubMed ID: 29246642
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Giulia I. Lane and Badrinath Konety's Letter to the Editor re: Bimal Bhindi, Igor Frank, Ross J. Mason, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol 2017;72:660-4.
    Bhindi B; Boorjian SA
    Eur Urol; 2018 Mar; 73(3):e70-e71. PubMed ID: 29097100
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Bimal Bhindi, Igor Frank, Ross J. Mason, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol 2017;72:660-4.
    Papadopoulos G; Fragkoulis C; Ntoumas K
    Eur Urol; 2018 Mar; 73(3):e52. PubMed ID: 29273411
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Bimal Bhindi, Igor Frank, Ross J. Mason, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol 2017;72:660-4.
    Lane GI; Konety B
    Eur Urol; 2018 Mar; 73(3):e69. PubMed ID: 29100814
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas's Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020;77:101-9.
    Del Giudice F; Catto JWF; Panebianco V
    Eur Urol; 2020 Apr; 77(4):e94-e95. PubMed ID: 32005552
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Georgios Papadopoulos, Georgios Stathouros and Konstantinos Doumas' Letter to the editor Re: Maxine Sun, Marco Bianchi, Jens Hansen, et al. Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur Urol 2012;62:696-703.
    Sun M; Bianchi M; Karakiewicz PI; Trinh QD
    Eur Urol; 2013 May; 63(5):e65-6. PubMed ID: 23395592
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Samuel Bishara and Jim Adshead's letter to the editor re: Brian J. Linder, Igor Frank, John C. Cheville, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 2013;63:839-45.
    Linder BJ; Boorjian SA
    Eur Urol; 2013 Sep; 64(3):e49-50. PubMed ID: 23787355
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Takeshi Takahashi's Letter to the Editor re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting functional outcomes after partial and radical nephrectomy. Eur Urol 2019;75:766-72. Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?
    Bhindi B; Lohse CM; Schulte PJ; Mason RJ; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
    Eur Urol; 2019 Sep; 76(3):e67-e68. PubMed ID: 31167750
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to Claire Vale, David Fisher, Jayne Tierney, Ian White, Matthew Sydes, and James Carpenter's Letter to the Editor re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.10.002.
    Wallis CJD; Klaassen Z
    Eur Urol; 2018 Mar; 73(3):e51. PubMed ID: 29224912
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Brian J. Linder, Igor Frank, John C. Cheville, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 2013;63:839-45.
    Bishara S; Adshead J
    Eur Urol; 2013 Sep; 64(3):e48. PubMed ID: 23769589
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Siebren Dijkstra and Carl J. Wijburg's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol 2018;74:465-71. Can the Pattern of Cancer Recurrence Truly be Assigned to the Surgical Modality?
    Bochner BH; Dalbagni G
    Eur Urol; 2019 May; 75(5):e138-e139. PubMed ID: 30712972
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.10.002.
    Vale C; Fisher D; Tierney J; White I; Sydes M; Carpenter J
    Eur Urol; 2018 Mar; 73(3):e49-e50. PubMed ID: 29233663
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.
    Trock BJ; Karnes RJ
    Eur Urol; 2017 Dec; 72(6):e158-e159. PubMed ID: 28576503
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Francesco Montorsi and Giorgio Gandaglia's letter to the editor re: Georgios Gakis, Stephen A. Boorjian, Alberto Briganti, et al. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur urol 2014;66:191-9.
    Gakis G; Stief CG
    Eur Urol; 2014 Dec; 66(6):e109-10. PubMed ID: 25204223
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Konstantinos P. Economopoulos, Aliki Stamou, and Theodoros N. Sergentanis' letter to the editor re: Luis Felipe Brandao, Riccardo Autorino, Humberto Laydner, et al. Robotic versus laparoscopic adrenalectomy: a systematic review and meta-analysis. Eur Urol 2014;65:1154-61.
    Brandao L; Zargar H; Autorino R
    Eur Urol; 2015 Feb; 67(2):e33-4. PubMed ID: 25308969
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to André Pontes-Silva's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561-70.
    Ilie G; Rutledge RDH
    Eur Urol; 2024 Feb; 85(2):e45-e46. PubMed ID: 37743197
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Zhipeng Mai, Weigang Yan, and Zhien Zhou's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561-70.
    Ilie G; Rutledge RDH
    Eur Urol; 2023 Aug; 84(2):e48-e49. PubMed ID: 37244817
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Matthias May, Ingmar Wolff, and Sabine D. Brookman-May's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561-70.
    Ilie G; Rutledge RDH
    Eur Urol; 2024 Feb; 85(2):e49-e50. PubMed ID: 37743193
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation.
    Giacalone NJ; Niemierko A; Shipley WU; Efstathiou JA
    Eur Urol; 2017 Sep; 72(3):e64-e65. PubMed ID: 28642020
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to M.V. Meng's Letter to the Editor re: H. Baumert et al. The use of polymer (Hem-o-lok) clips for management of the renal hilum during laparoscopic nephrectomy. Eur Urol 2006;49:816-9 and P.L. Steinberg et al. re: H. Baumert et al. The use of polymer (Hem-o-lok) clips for management of the renal hilum during laparoscopic nephrectomy. Eur Urol 2006;49:816-9. Eur Urol 2007;51:572-3.
    O'Kane HF; Nambirajan T
    Eur Urol; 2007 May; 51(5):1449. PubMed ID: 17229516
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.